-
Kelun Pharmaceutical's Gadoxetate Disodium Injection Obtained Drug Registration Approval
Time of Update: 2021-11-05
After review, the drug meets the relevant requirements of drug registration, approved for registration, and issued a drug registration certificate for the detection of focal liver lesions .
Compared with other MRI contrast agents, it can improve the detection rate of focal liver lesions and the accuracy of qualitative diagnosis, especially for small lesions.
-
Novo Nordisk reached a settlement for $100 million in shareholder class action insulin pricing opaque
Time of Update: 2021-11-05
CompilationAspirinOn September 24, 2021, in a 2017 lawsuit filed in the Federal District Court of New Jersey after shareholders claimed that the insulin pricing disclosed by them was opaque, Novo Nordisk agreed to pay the plaintiff a settlement agreement of US$100 million .
-
Novavax submits emergency use application to WHO
Time of Update: 2021-11-05
(NASDAQ: NVAX), a biotechnology company dedicated to the development and commercialization of next-generation vaccines for severe infectious diseases, cooperates with it Partner Serum Institute of India Private Limited (SII) announced today that the two companies have submitted relevant regulatory documents to the World Health Organization (WHO) to apply for Novavax recombinant nanoparticle protein new coronary pneumonia vaccine candidates using Matrix-M™ adjuvant.
-
Is it difficult for manufacturers of Chinese medicinal materials to increase prices?
Time of Update: 2021-11-05
However, due to the closure of villages and roads in many Chinese medicinal materials production areas during the epidemic period, transportation was blocked, causing the market to bottom out or out of stalls, and the prices of some varieties still rose .
-
391 pharmaceutical companies posted their transcripts for the first half of the year!
Time of Update: 2021-11-05
have also reached new highs; 13 companies such as Zhifei Bio, Mindray Medical, and Hengrui Medical The profit exceeded 2 billion yuan; the gross profit margin of 18 companies including Ellis, Biotech, and Wuwu Biotech exceeded 90% .
-
Check more!
Time of Update: 2021-11-05
At the same time that the pharmacy cleaned up the windows and advertisements on the exterior wall, the law enforcement team also issued a "Notice of Ordering Correction" to its operators, requesting them to rectify the existing problems immediately, and no relevant violations should occur again .
-
JAK inhibitor gets FDA approval again to treat fatal complications of stem cell transplantation
Time of Update: 2021-11-05
Today, Incyte announced that the US FDA has approved its JAK inhibitor Jakafi (ruxolitinib) to expand its indications for the treatment of chronic graft-versus-host disease (GVHD) adults and children over 12 years old .
-
Pfizer's oral JAK inhibitor Xeljanz receives two new indications in the EU
Time of Update: 2021-11-05
CompilationTom LeeA few days ago, the European Commission (EC) announced the approval of Pfizer’s JAK inhibitor oral drug Xeljanz (tofacitinib) for the treatment of young children with active polyarticular joints who are two years of age and older who have first used anti-rheumatic drugs (DMARDs) and have poor response to treatment.
-
National Cheng Kung University finally clears customs
Time of Update: 2021-11-05
In the announcement, the China Securities Regulatory Commission announced that it agreed to the registration of the initial public offering of shares on the National Cheng Kung University Biotech Innovation Board in accordance with legal procedures, and stated that relevant companies and their underwriters will negotiate with the Shanghai Stock Exchange to determine the issuance schedule and publish prospectus documents one after another .
-
Phase 3 clinical results of C3 complement inhibitors for the treatment of age-related macular degeneration released
Time of Update: 2021-11-05
On September 9, Apellis announced the top-line results obtained in two phase 3 clinical trials, DERBY and OAKS, in the research pegcetacoplan targeting the complement C3 protein .
com/news-release/2021/09/09/2294782/0/en/Apellis-Announces-Top-Line-Results-from-Phase-3-DERBY-and-OAKS-Studies-in-Geographic-Atrophy-GA -and-Plans-to-Submit-NDA-to-FDA-in-the-First-Half-of-2022.
-
Latest disclosure!
Time of Update: 2021-11-05
In the first half of 2021, the sales revenue of antibiotics and other businesses was 836 million yuan, an increase of 30.
The sales revenue of functional food and other businesses in the first half of 2021 was 672 million yuan, a decrease of 5.
-
Promote "what can be done" and crack the "can't be done" where does confidence in Chinese medicine come from
Time of Update: 2021-11-05
In the inheritance and development of more than two thousand years, traditional Chinese medicine has created world-renowned achievements, formed a systematic and complete scientific theory, and establ
-
Chuangxiang Biotechnology completes the first patient's first dosing for the global Phase 2 clinical study in the U.S.
Time of Update: 2021-11-05
Chuangxiang Bio announced that the global phase 2 clinical study ASPIRE, which aims to evaluate the efficacy of izokibep in the treatment of ankylosing spondylitis, completed the first administration of the first patient in California on August 25, Beijing time.
-
Kelun Pharmaceutical's Ceftazidime/5% Glucose Injection was approved for drug registration
Time of Update: 2021-11-05
On September 28, Kelun Pharmaceutical issued an announcement stating that its subsidiary Hunan Kelun Pharmaceutical’s chemical drug "Ceftazidime for Injection/5% Glucose Injection" has recently been approved for drug registration by the National Medical Products Administration.
-
Cholangiocarcinoma therapy Gavo-cel received FDA orphan drug designation
Time of Update: 2021-11-05
The company's TRuC-T cell candidate product Gavo-cel, which targets solid tumors, is currently being studied in phase 1/2 clinical trials to treat mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, and malignant pleura/peritoneum Mesothelioma and cholangiocarcinoma .
-
Innovent announces the use of Daboshu (Xindi Lizumab injection) combined with Dayoutong (bevacizumab injection) and chemotherapy for the treatment of EGFR-mutant non-squamous non-small cell lung cancer that has failed EGFR-TKI treatment Phase III clinical study reached
Time of Update: 2021-11-05
San Francisco and Suzhou, China October 18, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the
-
Viewing the Development Mode of Pharmaceutical Retailing from the Low Frequency of Medical Treatment
Time of Update: 2021-11-05
In a pharmaceutical retail market that mainly meets low-frequency demand, in addition to measuring the incidence, income level and consumption preferences of the population that can be covered by the pharmacy or online, the key is how to increase the frequency and promote the actual arrival of users.
-
Characteristics of the Japanese drugstore market: oligopoly, professionalism and convenience
Time of Update: 2021-11-05
Under this business logic, the development strategy of drugstores is more biased towards large and medium-sized convenience stores, with the main features of attracting young and middle-aged women in business districts and the elderly in the community .
-
TOP10 sales in Beijing, Shanghai and Guangzhou are released!
Time of Update: 2021-11-05
Anti-tumor drugs are still the main drug in the three cities of Beijing, Shanghai and Guangzhou; Lipitor has grown against the trend, lung cancer star drugs have declined for the first time, and the sales of the three major brands have doubled; Zhu, CSPC, Qilu, Yangtze River.
-
CSPC will win $9 billion star anticoagulant
Time of Update: 2021-11-05
In 2020, Bristol-Myers Squibb’s Eliquis global sales exceeded 9 billion U.
In 2020, Bristol-Myers Squibb's Eliquis (apixaban tablets) global sales exceeded 9.
Bristol-Myers Squibb Eliquis global sales (unit: million dollars)Source: Mynet.
